Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab

Pant, Shubham; Martin, Ludmila Katherine; Geyer, Susan; Wei, Lai; Loon, Katherine Van; Sommovilla, Nilli; Zalupski, Mark M.; Iyer, Renuka; Fogelman, David R.; Ko, Andrew H.; Bekaii‐Saab, Tanios

doi:10.1002/cncr.28648

Cited by 23 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings can be explained by the fact that hypoalbuminemia may weaken the human defense mechanisms, blunting the therapeutic response and further accelerating the tumor progression. Further, in patients who suffer from simultaneous nutritional decline, they are more likely to have reduced ability to endure aggressive anti-cancer therapeutics [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma

et al. 2018

View full text Add to dashboard Cite

BackgroundCoagulation and nutrition play important roles in cancer progression. The aim of the present study is to evaluate the prognostic value of the preoperative fibrinogen/albumin ratio (FAR) in surgical patients with soft tissue sarcoma (STS) and to compare this value with other inflammatory biomarkers. In addition, we investigated the relationship between FAR and the clinicopathological characteristics of STS patients.MethodsWe included 310 STS patients in this retrospective study. Kaplan-Meier curves, univariate and multivariate Cox proportional models were used in the prognostic analyses.ResultsAccording to the receiver operating characteristic (ROC) analysis, the optimal FAR cut-off value was 0.0726. The FAR exhibited a greater area under the curve (AUC) value (0.680) than did the NLR and PLR. An elevated FAR (≥0.0726) was significantly associated with an old age, large tumor size, deep tumor location, high tumor grade, and advanced American Joint Committee on Cancer (AJCC) stage.Patients with an increased FAR had a shorter median survival time and a lower 5-year overall survival (OS) rate than did those with a low FAR (61.0 vs115.8 months, P < 0.001; 56.7% vs 82.4%, P < 0.001, respectively). Multivariate analysis indicated FAR (Hazard ratio (HR) 1.907, 95% confidence interval (CI) 1.161–3.132, P < 0.001) to be an independent prognostic factor for OS, as were tumor depth, grade and PLR.ConclusionsPreoperative FAR is associated with tumor progression and can be considered an independent factor for OS of resected STS patients.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4856-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This finding is explained by the fact that hypoalbuminemia can cause a series of detrimental clinical effects, including edema, impaired organ function and microenvironmental variations, thereby reducing treatment response and leading to tumor progression. In addition, concomitant nutritional decline reduces a patient's capacity to endure aggressive cancer therapy [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the C-reactive protein/Albumin Ratio (CAR) in patients with operable soft tissue sarcoma

et al. 2017

View full text Add to dashboard Cite

BackgroundThe preoperative C-reactive protein/Albumin ratio (CAR) is valuable for predicting the prognosis of patients with various types of cancers. The aim of the present study is to investigate the prognostic value of the preoperative CAR and compare it with other systemic inflammatory response markers in patients with soft tissue sarcoma (STS).MethodsThis retrospective study included 206 patients with STS. The optimal cutoff value of the CAR was determined by receiver operating characteristic (ROC) analysis. The impact of the CAR and other clinicopathological features on overall survival (OS) and disease-free survival (DFS) was evaluated using univariate and multivariate Cox regression analyses. Kaplan-Meier survival analyses were used to compare groups classified by the CAR. Additionally, the area under the receiver operating characteristic curve (AUC) was used to compare the predictive ability of the CAR, high-sensitivity modified Glasgow prognostic score (Hs-mGPS), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR).ResultsThe optimal cut-off value of the CAR was 0.1035 according to the ROC analysis. An increased CAR (≥0.1035) was significantly associated with older age, larger tumor size, deep tumor location, higher tumor grade and more advanced American Joint Committee on Cancer (AJCC) stage (all P<0.05). Patients with an elevated CAR (≥0.1035) exhibited a shorter median survival time and lower 5-year OS rate than those with a CAR<0.1035 (68.2 vs 115.8 months, P = 0.000; 44.6% vs 80.9%, P = 0.000, respectively). The results of a multivariate analysis indicated that the CAR (Hazard ratio (HR) 2.47, 95% confidence interval (CI) 1.47-4.14, P = 0.001) was an independent prognostic factor for OS along with tumor grade (P<0.05). Additionally, the CAR exhibited a greater AUC value (0.662) than the NLR and PLR, but the value was equal to the Hs-mGPS.ConclusionsThe preoperative CAR is an independent prognostic factor predicting prognosis in STS and exhibits superior prognostic ability compared to the established inflammation-based prognostic indices.

show abstract

“…Previous studies have established reduced serum albumin as a marker of poor prognosis in cancer patients [6,7,9,[13][14][15] and also of a patient's capacity to endure aggressive cancer therapy [16,17]. A reduced albumin level has previously been attributed to the consuming nature of the cancer [3,7].…”

Section: Discussionmentioning

confidence: 99%

Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

et al. 2016

View full text Add to dashboard Cite

Background. In cancer patients, reduced serum albumin has been described as a marker for global declining health and poor prognosis. Our aim was to investigate the association of albumin concentrations with the occurrence of venous thromboembolism (VTE) and mortality in patients with cancer. Methods. This investigation was performed in the framework of the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study. We included 1,070 patients with active cancer and assayed serum albumin from venous blood taken at study inclusion. Risk for occurrence of VTE was calculated in a proportional subdistribution hazard regression model with respect to competing risk of death and adjusted for cancer site, leukocyte count, estimated glomerular filtration rate, and cholinesterase.

show abstract

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab

Cited by 23 publications

References 29 publications

Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma

Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma

Prognostic value of the C-reactive protein/Albumin Ratio (CAR) in patients with operable soft tissue sarcoma

Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

Contact Info

Product

Resources

About